LEQVIO® (inclisiran) injection 284 mg/1.5 mL

LEQVIO® Dosing and Administration:

INJECTION INFORMATION FOR YOUR PRACTICE



LEQVIO PRODUCT INFORMATION

- Single-dose prefilled syringe of LEQVIO 284 mg/1.5 mL for subcutaneous use[1]
  - 27 gauge 1/2-inch needle[2]
- Sterile, clear and colorless to pale yellow solution[1]
  - This color variation is normal and has no impact on the overall quality of LEQVIO
- Store at room temperature, 68 °F to 77 °F (20 °C to 25 °C)[1]
- Does not require refrigeration

WHO CAN ADMINISTER LEQVIO?

LEQVIO should be administered by a health care provider.[1]*

*Physician, nurse practitioner, physician assistant, or other licensed practitioners.

In-office administration gives you the confidence that your patients received their dose[1]



HOW IS LEQVIO ADMINISTERED?

LEQVIO is administered in just 2 steps†:

Step 1: Inspect the syringe

- Check the liquid medicine in the syringe before you give the injection—the solution should be clear and colorless to pale yellow[1]

Step 2: Inject the medication

- Inject subcutaneously into the abdomen, upper arm, or thigh[1]
- Injections should not be given in areas of active skin disease or injury, such as sunburns, skin rashes, inflammation, or skin infections[1]

No specific label requirement for post-injection–related safety monitoring.

†Clean the injection site with an alcohol swab and use standard aseptic technique when administering injection.

INDICATION

LEQVIO (inclisiran) injection is indicated as an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density lipoprotein cholesterol (LDL-C).

IMPORTANT SAFETY INFORMATION

Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, and bronchitis.

Please click here for LEQVIO full Prescribing Information.

NOVARTIS

LEQVIO®
(inclisiran) injection 284 mg/1.5 mL

2 INITIAL DOSES, THEN 2 DOSES A YEAR[1]

INITIAL DOSE

ANOTHER AT 3 MONTHS[1]

Recommended dose:
One prefilled syringe of LEQVIO 284 mg/1.5 mL.[1]

The LEQVIO dosing regimen may integrate seamlessly into a patient's health care routine[1]

ADDITIONAL CONSIDERATIONS

LEQVIO is administered in combination with maximally tolerated statin therapy.

- **Administration:** Office should schedule the 3-month visit and the following 6-month visit at the time of the initial injection
- **Missed dose:** If a planned dose is missed by less than 3 months, administer LEQVIO and maintain dosing according to the patient's original schedule. If a planned dose is missed by more than 3 months, start a new dosing schedule[1]*
- **Injection site reactions:**
  - Let patients know that in clinical trials, injection site reactions were predominantly mild or occasionally moderate and did not persist over time[1,3]
  - Advise patients to seek medical attention if injection site irritation persists

*LEQVIO is administered initially, again at 3 months, and then once every 6 months.

IMPORTANT SAFETY INFORMATION

Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, and bronchitis.

Please click here for LEQVIO full Prescribing Information.

References: 1. Leqvio. Prescribing information. Novartis Pharmaceuticals Corp. **2.** Data on file. LEQVIO Container Closure System. Novartis Pharmaceuticals Corp; 2022. **3.** Data on file. Novartis Pharmaceuticals Corp; 2019.

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080